Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors

Michele Andreucci, Teresa Faga, Antonio Pisani, Massimo Sabbatini, Domenico Russo, Ashour Michael, Michele Andreucci, Teresa Faga, Antonio Pisani, Massimo Sabbatini, Domenico Russo, Ashour Michael

Abstract

Contrast-induced nephropathy (CIN) is an iatrogenic acute renal failure (ARF) occurring after the intravascular injection of iodinated radiographic contrast media. During the past several years, in many patients undergoing computed tomography, iodinated contrast media have not been used for the fear of ARF, thereby compromising the diagnostic procedure. But recent studies have demonstrated that CIN is rarely occurring in patients with normal renal function and that preexisting chronic renal failure and/or diabetes mellitus represent(s) predisposing condition(s) for its occurrence. After the description of CIN and its epidemiology and pathophysiology, underlying the important role played by dehydration and salt depletion, precautions for prevention of CIN are listed, suggested, and discussed. Maximum priority has to be given to adequate hydration and volume expansion prior to radiographic procedures. Other important precautions include the need for monitoring renal function before, during, and after contrast media injection, discontinuation of potentially nephrotoxic drugs, use of either iodixanol or iopamidol at the lowest dosage possible, and administration of antioxidants. A long list of references is provided that will enable readers a deep evaluation of the topic.

Figures

Figure 1
Figure 1
The complex mechanisms by which iodinated radiographic contrast media cause the fall of GFR.

References

    1. Bartels E. D., Brun G. C., Gammeltoft A., Gjorup P. A. Acute anuria following intravenous pyelography in a patient with myelomatosis. Acta Medica Scandinavica. 1954;150:297–302.
    1. Mussap M., Merlini G. Pathogenesis of renal failure in multiple myeloma: any role of contrast media? BioMed Research International. 2014;2014 doi: 10.1155/2014/167125.167125
    1. Gleeson T. G., Bulugahapitiya S. Contrast-induced nephropathy. American Journal of Roentgenology. 2004;183(6):1673–1689. doi: 10.2214/ajr.183.6.01831673.
    1. Meinel F. G., de Cecco C. N., Schoepf U. J., Katzberg R. Contrast-induced acute kidney injury: definition, epidemiology, and outcome. BioMed Research International. 2014;2014 doi: 10.1155/2014/859328.859328
    1. Berlyne N., Berlyne G. M. Acute renal failure following intravenous pyelography with hypaque. Acta Medica Scandinavica. 1962;171:39–41.
    1. Rao Q. A., Newhouse J. H. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology. 2006;239(2):392–397. doi: 10.1148/radiol.2392050413.
    1. Elicker B. M., Cypel Y. S., Weinreb J. C. IV contrast administration for CT: a survey of practices for the screening prevention of contrast nephropathy. The American Journal of Roentgenology. 2006;186(6):1651–1658. doi: 10.2214/AJR.05.0407.
    1. Katzberg R. W., Newhouse J. H. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010;256(1):21–28. doi: 10.1148/radiol.10092000.
    1. Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine. 1999;130(6):461–470. doi: 10.7326/0003-4819-130-6-199903160-00002.
    1. Levey A. S., Stevens L. A., Schmid C. H., Zhang Y., Castro A. F., III, Feldman H. I., Kusek J. W., Eggers P., Lente F. V., Greene T., Coresh J. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine. 2009;150(9):604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
    1. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580.
    1. Andreucci M., Solomon R., Tasanarong A. Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. BioMed Research International. 2014;2014 doi: 10.1155/2014/741018.741018
    1. Briguori C., Colombo A., Violante A., Balestrieri P., Manganelli F., Elia P. P., Golia B., Lepore S., Riviezzo G., Scarpato P., Focaccio A., Librera M., Bonizzoni E., Ricciardelli B. Standard vs. double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. European Heart Journal. 2004;25(3):206–211. doi: 10.1016/j.ehj.2003.11.016.
    1. Andreucci V. E., Fuiano G., Russo D., Andreucci M. Vasomotor nephropathy in the elderly. Nephrology Dialysis Transplantation. 1998;13(supplement 7):17–24.
    1. Andreucci V. E., Fuiano G., Stanziale P., Andreucci M. Role of renal biopsy in the diagnosis and prognosis of acute renal failure. Kidney International, Supplement. 1998;53(66):S91–S95.
    1. Andreucci M. Side effects of radiographic contrast media. BioMed Research International. 2014;2014 doi: 10.1155/2014/872574.872574
    1. Curtis L. M., Agarwal A. HOpe for contrast-induced acute kidney injury. Kidney International. 2007;72(8):907–909. doi: 10.1038/sj.ki.5002530.
    1. Solomon R. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clinical Journal of the American Society of Nephrology. 2008;3(5):1242–1243. doi: 10.2215/CJN.03470708.
    1. Weisbord S. D., Palevsky P. M. Prevention of contrast-induced nephropathy with volume expansion. Clinical Journal of the American Society of Nephrology. 2008;3(1):273–280. doi: 10.2215/CJN.02580607.
    1. Mehran R., Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney International. Supplement. 2006:S11–S15.
    1. Bruce R. J., Djamali A., Shinki K., Michel S. J., Fine J. P., Pozniak M. A. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. American Journal of Roentgenology. 2009;192(3):711–718. doi: 10.2214/AJR.08.1413.
    1. McDonald R. J., McDonald J. S., Bida J. P., Carter R. E., Fleming C. J., Misra S., Williamson E. E., Kallmes D. F. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology. 2013;267(1):106–118. doi: 10.1148/radio.12121823/-/DC1.
    1. McDonald J. S., McDonald R. J., Comin J., Williamson E. E., Katzberg R. W., Murad M. H., Kallmes D. F. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology. 2013;267(1):119–128. doi: 10.1148/radiol.12121460.
    1. Mitchell A. M., Jones A. E., Tumlin J. A., Kline J. A. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clinical Journal of the American Society of Nephrology. 2010;5(1):4–9. doi: 10.2215/CJN.05200709.
    1. Davenport M. S., Khalatbari S., Cohan R. H., Dillman J. R., Myles J. D., Ellis J. H. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology. 2013;268(3):719–728. doi: 10.1148/radiol.13122276.
    1. Davenport M. S., Khalatbari S., Dillman J. R., Cohan R. H., Caoili E. M., Ellis J. H. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology. 2013;267(1):94–105. doi: 10.1148/radiol.12121394.
    1. Rudnick M., Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clinical Journal of the American Society of Nephrology. 2008;3(1):263–272. doi: 10.2215/CJN.03690907.
    1. Fuiano G., Mancuso D., Indolfi C., Mongiardo A., Sabbatini M., Conte G., De Nicola L., Minutolo R., Mazza G., Cianfrone P., Andreucci M. Early detection of progressive renal dysfunction in patients with coronary artery disease. Kidney International. 2005;68(6):2773–2780. doi: 10.1111/j.1523-1755.2005.00748.x.
    1. Solomon R. J., Mehran R., Natarajan M. K., Doucet S., Katholi R. E., Staniloae C. S., Sharma S. K., Labinaz M., Gelormini J. L., Barrett B. J. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clinical Journal of the American Society of Nephrology. 2009;4(7):1162–1169. doi: 10.2215/CJN.00550109.
    1. Scanlon P. J., Faxon D. P., Audet A. M., Carabello B., Dehmer G. J., Eagle K. A., Legako R. D., Leon D. F., Murray J. A., Nissen S. E., Pepine C. J., Watson R. M., Ritchie J. L., Gibbons R. J., Cheitlin M. D., Gardner T. J., Garson A., Jr., Russell R. O., Jr., Ryan T. J., Smith S. C., Jr. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation. 1999;33(6):1756–1824.
    1. Murphy S. W., Barrett B. J., Parfrey P. S. Contrast nephropathy. Journal of the American Society of Nephrology. 2000;11(1):177–182.
    1. Heyman S. N., Rosen S., Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clinical Journal of the American Society of Nephrology. 2008;3(1):288–296. doi: 10.2215/CJN.02600607.
    1. Bucher A. M., de Cecco C. N., Schoepf U. J., Meinel F. G., Krazinski A. W., Spearman J. V., McQuiston A. D., Wang R., Bucher J., Vogl T. J., Katzberg R. W. Is contrast medium osmolality a causal factor for contrast-induced nephropathy? BioMed Research International. 2014;2014 doi: 10.1155/2014/931413.931413
    1. Andreucci M., Faga T., Pisani A., Sabbatini M., Michael A. Acute kidney injury by radiographic contrast media: pathogenesis and prevention. BioMed Research International. 2014;2014 doi: 10.1155/2014/362725.362725
    1. Andreucci M., Faga T., Pisani A., Sabbatini M., Michael A. Pathogenesis of acute renal failure induced by iodinated radiographic contrast media. Austin Journal of Nephrology and Hypertension. 2014;1(1):1–6.
    1. Pisani A., Riccio E., Andreucci M., Faga T., Ashour M., Di Nuzzi A., Mancini A., Sabbatini M. Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy. BioMed Research International. 2013;2013 doi: 10.1155/2013/868321.868321
    1. Giaccia A. J., Simon M. C., Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes and Development. 2004;18(18):2183–2194. doi: 10.1101/gad.1243304.
    1. Sabbatini M., Santillo M., Pisani A., et al. Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury. American Journal of Physiology: Renal Physiology. 2006;290(6):F1408–F1415. doi: 10.1152/ajprenal.00304.2005.
    1. Heyman S. N., Rosen S., Khamaisi M., Idée J.-M., Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Investigative Radiology. 2010;45(4):188–195. doi: 10.1097/RLI.0b013e3181d2eed8.
    1. Dawson P., Harrison M. J. G., Weisblatt E. Effect of contrast media on red cell filtrability and morphology. British Journal of Radiology. 1983;56(670):707–710. doi: 10.1259/0007-1285-56-670-707.
    1. Sendeski M. M. Pathophysiology of renal tissue damage by iodinated contrast media. Clinical and Experimental Pharmacology and Physiology. 2011;38(5):292–299. doi: 10.1111/j.1440-1681.2011.05503.x.
    1. Pacher P., Beckman J. S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiological Reviews. 2007;87(1):315–424. doi: 10.1152/physrev.00029.2006.
    1. Pisani A., Sabbatini M., Riccio E., Rossano R., Andreucci M., Capasso C., De Luca V., Carginale V., Bizzarri M., Borrelli A., Schiattarella A., Santangelo M., Mancini A. Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. Clinical and Experimental Nephrology. 2014;18(3):424–431. doi: 10.1007/s10157-013-0828-2.
    1. Caiazza A., Russo L., Sabbatini M., Russo D. Hemodynamic and tubular changes induced by contrast media. BioMed Research International. 2014;2014 doi: 10.1155/2014/578974.578974
    1. Gospos C., Freudenberg N., Staubesand J., Mathias K., Papacharlampos X. The effect of contrast media on the aortic endothelium of rats. Radiology. 1983;147(3):685–688. doi: 10.1148/radiology.147.3.6844605.
    1. Hardiek K., Katholi R. E., Ramkumar V., Deitrick C. Proximal tubule cell response to radiographic contrast media. The American Journal of Physiology—Renal Physiology. 2001;280(1):F61–F70.
    1. Heinrich M. C., Kuhlmann M. K., Grgic A., Heckmann M., Kramann B., Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology. 2005;235(3):843–849. doi: 10.1148/radiol.2353040726.
    1. Michael A., Faga T., Pisani A., Riccio E., Bramanti P., Sabbatini M., Navarra M., Andreucci M. Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media. BioMed Research International. 2014;2014 doi: 10.1155/2014/249810.249810
    1. Andreucci M., Michael A., Kramers C., Park K. M., Chen A., Matthaeus T., Alessandrini A., Haq S., Force T., Bonventre J. V. Renal ischemia/reperfusion and ATP depletion/repletion in LLC-PK1 cells result in phosphorylation of FKHR and FKHRL1. Kidney International. 2003;64(4):1189–1198. doi: 10.1046/j.1523-1755.2003.00204.x.
    1. Andreucci M., Fuiano G., Presta P., Lucisano G., Leone F., Fuiano L., Bisesti V., Esposito P., Russo D., Memoli B., Faga T., Michael A. Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. Cell Proliferation. 2009;42(4):554–561. doi: 10.1111/j.1365-2184.2009.00617.x.
    1. Andreucci M. Contrast media and nephrotoxicity: a molecular conundrum. Giornale Italiano di Nefrologia. 2011;28(4, article 355)
    1. Quintavalle C., Brenca M., de Micco F., Fiore D., Romano S., Romano M. F., Apone F., Bianco A., Zabatta M. A., Troncone G., Briguori C., Condorelli G. In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis. Cell Death and Disease. 2011;2(5, article e155) doi: 10.1038/cddis.2011.38.
    1. Andreucci M., Faga T., Lucisano G., Uccello F., Pisani A., Memoli B., Sabbatini M., Fuiano G., Michael A. Mycophenolic acid inhibits the phosphorylation of NF-κB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. Chemico-Biological Interactions. 2010;185(3):253–262. doi: 10.1016/j.cbi.2010.03.019.
    1. Andreucci M., Fuiano G., Presta P., Esposito P., Faga T., Bisesti V., Procino A., Altieri V., Tozzo C., Memoli B., Michael A. Radiocontrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells. Biochemical Pharmacology. 2006;72(10):1334–1342. doi: 10.1016/j.bcp.2006.08.008.
    1. Andreucci M., Faga T., Russo D., Bertucci B., Tamburrini O., Pisani A., Sabbatini M., Fuiano G., Michael A. Differential activation of signaling pathways by low-osmolar and Iso-osmolar radiocontrast agents in human renal tubular cells. Journal of Cellular Biochemistry. 2014;115(2):281–289. doi: 10.1002/jcb.24662.
    1. Andreucci M., Lucisano G., Faga T., et al. Differential activation of signaling pathways involved in cell death, survival and inflammation by radiocontrast media in human renal proximal tubular cells. Toxicological Sciences. 2011;119(2):408–416. doi: 10.1093/toxsci/kfq332.
    1. Lee H.-C., Chang J.-G., Yen H.-W., Liu I.-H., Lai W.-T., Sheu S.-H. Ionic contrast media induced more apoptosis in diabetic kidney than nonionic contrast media. Journal of Nephrology. 2011;24(3):376–380. doi: 10.5301/JN.2010.5784.
    1. Cunha M. A., Schor N. Effects of gentamicin, lipopolysaccharide, and contrast media on immortalized proximal tubular cells. Renal Failure. 2002;24(5):655–658. doi: 10.1081/JDI-120013970.
    1. Peer A., Averbukh Z., Berman S., Modai D., Averbukh M., Weissgarten J. Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells. Investigative Radiology. 2003;38(3):177–182. doi: 10.1097/00004424-200303000-00007.
    1. Yang D., Yang D., Jia R., Tan J. Na+/Ca2+ exchange inhibitor, KB-R7943, attenuates contrast-induced acute kidney injury. Journal of Nephrology. 2013;26(5):877–885. doi: 10.5301/jn.5000259.
    1. Duan S.-B., Liu F.-Y., Luo J.-A., Wu H.-W., Liu R.-H., Peng Y.-M., Yang X.-L. Nephrotoxicity of high- and low-osmolar contrast media: the protective role of amlodipine in a rat model. Acta Radiologica. 2000;41(5):503–507.
    1. Yang D., Yang D. Role of intracellular Ca2+ and Na+/Ca2+ exchanger in the pathogenesis of contrast-induced acute kidney injury. BioMed Research International. 2013;2013 doi: 10.1155/2013/678456.678456
    1. Seeliger E., Lenhard D. C., Persson P. B. Contrast media viscosity versus osmolality in kidney injury: lessons from animal studies. BioMed Research International. 2014;2014 doi: 10.1155/2014/358136.358136
    1. Aspelin P., Nilsson P. E., Schmid-Schönbein H., Schröder S., Simon R. Effect of four non-ionic contrast media on red blood cells in vitro. III. Deformability. Acta Radiologica. 1987;370:89–91.
    1. Hardeman M. R., Goedhart P., Koen I. Y. The effect of low-osmolar ionic and nonionic contrast media on human blood viscosity, erythrocyte morphology, and aggregation behavior. Investigative Radiology. 1991;26(9):810–819. doi: 10.1097/00004424-199109000-00006.
    1. Franke R. P., Scharnweber T., Fuhrmann R., Wenzel F., Kruger A., Mrowietz C., Jung F. Effect of radiographic contrast media on the spectrin/band3-network of the membrane skeleton of erythrocytes. PLoS ONE. 2014;9e89512
    1. Katzberg R. W. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology. 1997;204(2):297–312. doi: 10.1148/radiology.204.2.9240511.
    1. Aspelin P., Aubry P., Fransson S.-G., Strasser R., Willenbrock R., Berg K. J. Nephrotoxic effects in high-risk patients undergoing angiography. The New England Journal of Medicine. 2003;348(6):491–499. doi: 10.1056/NEJMoa021833.
    1. Taliercio C. P., Vlietstra R. E., Ilstrup D. M., Burnett J. C., Menke K. K., Stensrud S. L., Holmes D. R., Jr. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. Journal of the American College of Cardiology. 1991;17(2):384–390. doi: 10.1016/S0735-1097(10)80103-2.
    1. Barrett B. J., Carlisle E. J. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188(1):171–178. doi: 10.1148/radiology.188.1.8511292.
    1. Barrett B. J. Contrast nephrotoxicity. Journal of the American Society of Nephrology. 1994;5(2):125–137.
    1. Heinrich M. C., Häberle L., Müller V., Bautz W., Uder M. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology. 2009;250(1):68–86. doi: 10.1148/radiol.2501080833.
    1. Solomon R. J., Natarajan M. K., Doucet S., Sharma S. K., Staniloae C. S., Katholi R. E., Gelormini J. L., Labinaz M., Moreyra A. E. Cardiac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115(25):3189–3196. doi: 10.1161/CIRCULATIONAHA.106.671644.
    1. Reed M., Meier P., Tamhane U. U., Welch K. B., Moscucci M., Gurm H. S. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC: Cardiovascular Interventions. 2009;2(7):645–654. doi: 10.1016/j.jcin.2009.05.002.
    1. Bolognese L., Falsini G., Schwenke C., Grotti S., Limbruno U., Liistro F., Carrera A., Angioli P., Picchi A., Ducci K., Pierli C. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] trial) The American Journal of Cardiology. 2012;109(1):67–74. doi: 10.1016/j.amjcard.2011.08.006.
    1. Chalmers N., Jackson R. W. Comparison of iodixanol and iohexol in renal impairment. British Journal of Radiology. 1999;72:701–703. doi: 10.1259/bjr.72.859.10624328.
    1. Dong M., Jiao Z., Liu T., Guo F., Li G. Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials. Journal of Nephrology. 2012;25(3):290–301. doi: 10.5301/jn.5000067.
    1. Jost G., Pietsch H., Sommer J., Sandner P., Lengsfeld P., Seidensticker P., Lehr S., Hütter J., Sieber M. A. Retention of iodine and expression of biomarkers for renal damage in the kidney after application of iodinated contrast media in rats. Investigative Radiology. 2009;44(2):114–123. doi: 10.1097/RLI.0b013e318190fbd2.
    1. Dyvik K., Dyrstad K., Tronstad A. Relationship between viscosity and determined injection pressure in angiography catheters for common roentgen contrast media. Acta Radiologica. Supplementum. 1995;399:43–49.
    1. Martín-Mateo M. C., Sánchez-Portugal M., Iglesias S., de Paula A., Bustamante J. Oxidative stress in chronic renal failure. Renal Failure. 1999;21(2):155–167. doi: 10.3109/08860229909066980.
    1. Okamura D. M., Pennathur S., Pasichnyk K., et al. CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. Journal of the American Society of Nephrology. 2009;20(3):495–505. doi: 10.1681/ASN.2008010009.
    1. Hardiek K. J., Katholi R. E., Robbs R. S., Katholi C. E. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. Journal of Diabetes and its Complications. 2008;22(3):171–177. doi: 10.1016/j.jdiacomp.2006.11.002.
    1. Heyman S. N., Rosenberger C., Rosen S., Khamaisi M. Why is diabetes mellitus a risk factor for contrast-induced nephropathy? BioMed Research International. 2013;2013 doi: 10.1155/2013/123589.123589
    1. Morabito S., Pistolesi V., Benedetti G., Roma A. D., Colantonio R., Mancone M., Sardella G., Cibelli L., Ambrosino M., Polistena F., Pierucci A. Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography. Journal of Nephrology. 2012;25(6):1098–1107. doi: 10.5301/jn.5000101.
    1. Rudnick M. R., Goldfarb S., Tumlin J. Contrast-induced nephropathy: is the picture any clearer? Clinical Journal of the American Society of Nephrology. 2008;3(1):261–262. doi: 10.2215/CJN.04951107.
    1. Toprak O., Cirit M., Yesil M., Bayata S., Tanrisev M., Varol U., Ersoy R., Esi E. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrology Dialysis Transplantation. 2007;22(3):819–826. doi: 10.1093/ndt/gfl636.
    1. Khamaisi M., Raz I., Shilo V., Shina A., Rosenberger C., Dahan R., Abassi Z., Meidan R., Lecht S., Heyman S. N. Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. Kidney International. 2008;74(1):91–100. doi: 10.1038/ki.2008.112.
    1. Pflueger A., Larson T. S., Nath K. A., King B. F., Gross J. M., Knox F. G. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clinic Proceedings. 2000;75(12):1275–1283. doi: 10.4065/75.12.1275.
    1. Thomsen H. S., Morcos S. K. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. The British Journal of Radiology. 2003;76(908):513–518. doi: 10.1259/bjr/26964464.
    1. Morcos S. K., Thomsen H. S., Webb J. A. W. Contrast-media-induced nephrotoxicity: a consensus report. European Radiology. 1999;9(8):1602–1613. doi: 10.1007/s003300050894.
    1. Andreucci V. E., Russo D., Cianciaruso B., Andreucci M. Some sodium, potassium and water changes in the elderly and their treatment. Nephrology Dialysis Transplantation. 1996;11(9):9–17.
    1. Andreucci M. Radiographic contrast nephropathy. Giornale Italiano di Nefrologia. 2014;31(5) (Ita).
    1. Andreucci M., Federico S., Andreucci V. E. Edema and acute renal failure. Seminars in Nephrology. 2001;21(3):251–256. doi: 10.1053/snep.2001.21652.
    1. Seeliger E., Flemming B., Wronski T., Ladwig M., Arakelyan K., Godes M., Möckel M., Persson P. B. Viscosity of contrast media perturbs renal hemodynamics. Journal of the American Society of Nephrology. 2007;18(11):2912–2920. doi: 10.1681/ASN.2006111216.
    1. Cochran S. T., Wong W. S., Roe D. J. Predicting angiography-induced acute renal function impairment: clinical risk model. The American Journal of Roentgenology. 1983;141(5):1027–1033. doi: 10.2214/ajr.141.5.1027.
    1. Nikolsky E., Mehran R., Lasic Z., Mintz G. S., Lansky A. J., Na Y., Pocock S., Negoita M., Moussa I., Stone G. W., Moses J. W., Leon M. B., Dangas G. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney International. 2005;67(2):706–713. doi: 10.1111/j.1523-1755.2005.67131.x.
    1. Kolonko A., Kokot F., Więcek A. Contrast-associated nephropathy—old clinical problem and new therapeutic perspectives. Nephrology Dialysis Transplantation. 1998;13(3):803–806. doi: 10.1093/ndt/13.3.803.
    1. Ahuja T. S., Niaz N., Agraharkar M. Contrast-induced nephrotoxicity in renal allograft recipients. Clinical Nephrology. 2000;54(1):11–14.
    1. Ranucci M., Ballotta A., Kunkl A., de Benedetti D., Kandil H., Conti D., Mollichelli N., Bossone E., Mehta R. H. Influence of the timing of cardiac catheterization and the amount of contrast media on acute renal failure after cardiac surgery. The American Journal of Cardiology. 2008;101(8):1112–1118. doi: 10.1016/j.amjcard.2007.12.011.
    1. Kalyesubula R., Bagasha P., Perazella M. A. ACE-I/ARB therapy prior to contrast exposure: what should the clinician do? BioMed Research International. 2014;2014 doi: 10.1155/2014/423848.423848
    1. Neyra J. A., Shah S., Mooney R., Jacobsen G., Yee J., Novak J. E. Contrast-induced acute kidney injury following coronary angiography: a cohort study of hospitalized patients with or without chronic kidney disease. Nephrology Dialysis Transplantation. 2013;28(6):1463–1471. doi: 10.1093/ndt/gft082.
    1. Schoolwerth A. C., Sica D. A., Ballermann B. J., Wilcox C. S. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the council on the kidney in cardiovascular disease and the council for high blood pressure research of the american heart association. Circulation. 2001;104(16):1985–1991. doi: 10.1161/hc4101.096153.
    1. Cirit M., Toprak O., Yesil M., Bayata S., Postaci N., Pupim L., Esi E. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clinical Practice. 2006;104(1):c20–c27. doi: 10.1159/000093255.
    1. Kiski D., Stepper W., Brand E., Breithardt G., Reinecke H. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrology Dialysis Transplantation. 2010;25(3):759–764. doi: 10.1093/ndt/gfp582.
    1. Rim M. Y., Ro H., Kang W. C., Kim A. J., Park H., Chang J. H., Lee H. H., Chung W., Jung J. Y. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study. The American Journal of Kidney Diseases. 2012;60(4):576–582. doi: 10.1053/j.ajkd.2012.04.017.
    1. Umruddin Z., Moe K., Superdock K. ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy. Journal of Nephrology. 2012;25(5):776–781. doi: 10.5301/jn.5000059.
    1. Onuigbo M. A. C., Onuigbo N. T. C. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month mayo clinic study. Renal Failure. 2008;30(1):67–72. doi: 10.1080/08860220701742153.
    1. KDIGOKAKIW Group KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements. 2012;2(1):1–138.
    1. Andreucci M., Faga T., Sabbatini M., Pisani A., Russo D., Michael A. How to prevent Contrast-Induced Nephropathy in clinical practice. Journal of Clinical Nephrology and Research. 2014;1(1, article 1002)
    1. Susantitaphong P., Eiam-Ong S. Nonpharmacological strategies to prevent contrast-induced acute kidney injury. BioMed Research International. 2014;2014 doi: 10.1155/2014/463608.463608
    1. Solomon R. Contrast media: are there differences in nephrotoxicity among contrast media? BioMed Research International. 2014;2014 doi: 10.1155/2014/934947.934947
    1. Pattharanitima P., Tasanarong A. Pharmacological strategies to prevent contrast-induced acute kidney injury. BioMed Research International. 2014;2014 doi: 10.1155/2014/236930.236930
    1. Fliser D., Laville M., Covic A., Fouque D., Vanholder R., Juillard L., van Biesen W. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrology Dialysis Transplantation. 2012;27(12):4263–4272. doi: 10.1093/ndt/gfs375.
    1. Thomson K. Safe use of radiographic contrast media. Australian Prescriber. 2010;33(1):19–22.
    1. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney International. 2006;69:S16–S19. doi: 10.1038/sj.ki.5000369.
    1. Balemans C. E. A., Reichert L. J. M., van Schelven B. I. H., van Den Brand J. A. J. G., Wetzels J. F. M. Epidemiology of contrast material-induced nephropathy in the era of hydration. Radiology. 2012;263(3):706–713. doi: 10.1148/radiol.12111667/-/DC1.
    1. Thomsen H. S. Guidelines for contrast media from the European Society of Urogenital Radiology. American Journal of Roentgenology. 2003;181(6):1463–1471. doi: 10.2214/ajr.181.6.1811463.
    1. Ellis J. H., Cohan R. H. Prevention of contrast-induced nephropathy: an overview. Radiologic Clinics of North America. 2009;47(5):801–811. doi: 10.1016/j.rcl.2009.06.003.
    1. Solomon R., Dauerman H. L. Contrast-induced acute kidney injury. Circulation. 2010;122(23):2451–2455. doi: 10.1161/CIRCULATIONAHA.110.953851.
    1. Merten G. J., Burgess W. P., Gray L. V., Holleman J. H., Roush T. S., Kowalchuk G. J., Bersin R. M., Van Moore A., Simonton C. A., III, Rittase R. A., Norton H. J., Kennedy T. P. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. The Journal of the American Medical Association. 2004;291(19):2328–2334. doi: 10.1001/jama.291.19.2328.
    1. Masuda M., Yamada T., Mine T., Morita T., Tamaki S., Tsukamoto Y., Okuda K., Iwasaki Y., Hori M., Fukunami M. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. The American Journal of Cardiology. 2007;100(5):781–786. doi: 10.1016/j.amjcard.2007.03.098.
    1. Ozcan E. E., Guneri S., Akdeniz B., et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. American Heart Journal. 2007;154(3):539–544. doi: 10.1016/j.ahj.2007.05.012.
    1. Navaneethan S. D., Singh S., Appasamy S., Wing R. E., Sehgal A. R. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. American Journal of Kidney Diseases. 2009;53(4):617–627. doi: 10.1053/j.ajkd.2008.08.033.
    1. Tamura A., Goto Y., Miyamoto K., Naono S., Kawano Y., Kotoku M., Watanabe T., Kadota J. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. The American Journal of Cardiology. 2009;104(7):921–925. doi: 10.1016/j.amjcard.2009.05.034.
    1. Hoste E. A. J., De Waele J. J., Gevaert S. A., Uchino S., Kellum J. A. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 2010;25(3):747–758. doi: 10.1093/ndt/gfp389.
    1. Joannidis M., Schmid M., Wiedermann C. J. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wiener Klinische Wochenschrift. 2008;120(23-24):742–748. doi: 10.1007/s00508-008-1117-z.
    1. Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. Pediatric Cardiology. 2006;27(2):238–242. doi: 10.1007/s00246-005-1132-z.
    1. Pakfetrat M., Nikoo M. H., Malekmakan L., Tabandeh M., Roozbeh J., Nasab M. H., Ostovan M. A., Salari S., Kafi M., Vaziri N. M., Adl F., Hosseini M., Khajehdehi P. A comparison of sodium bicarbonate infusion versus normal saline infusion and its combination with oral acetazolamide for prevention of contrast-induced nephropathy: a randomized, double-blind trial. International Urology and Nephrology. 2009;41(3):629–634. doi: 10.1007/s11255-008-9520-y.
    1. Jang J. S., Jin H. Y., Seo J. S., Yang T. H., Kim D. K., Kim T. H., Urm S. H., Kim D. S., Seol S. H., Kim D. I., Cho K. I., Kim B. H., Park Y. H., Je H. G., Ahn J. M., Kim W. J., Lee J. Y., Lee S. W. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury—a systematic review and meta-analysis. Circulation Journal. 2012;76(9):2255–2265. doi: 10.1253/circj.CJ-12-0096.
    1. Reddan D., Laville M., Garovic V. D. Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? Journal of Nephrology. 2009;22(3):333–351.
    1. Zoungas S., Ninomiya T., Huxley R., Cass A., Jardine M., Gallagher M., Patel A., Vasheghani-Farahani A., Sadigh G., Perkovic V. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Annals of Internal Medicine. 2009;151(9):631–638. doi: 10.1059/0003-4819-151-9-200911030-00008.
    1. Burgess W. P., Walker P. J. Mechanisms of contrast-induced nephropathy reduction for saline (NaCl) and sodium bicarbonate (NaHCO3) BioMed Research International. 2014;2014 doi: 10.1155/2014/510385.510385
    1. Brar S. S., Shen A. Y.-J., Jorgensen M. B., Kotlewski A., Aharonian V. J., Desai N., Ree M., Shah A. I., Burchette R. J. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA—Journal of the American Medical Association. 2008;300(9):1038–1046. doi: 10.1001/jama.300.9.1038.
    1. Brar S. S., Hiremath S., Dangas G., Mehran R., Brar S. K., Leon M. B. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clinical Journal of the American Society of Nephrology. 2009;4(10):1584–1592. doi: 10.2215/CJN.03120509.
    1. Shavit L., Korenfeld R., Lifschitz M., Butnaru A., Slotki I. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. Journal of Interventional Cardiology. 2009;22(6):556–563. doi: 10.1111/j.1540-8183.2009.00500.x.
    1. Vasheghani-Farahani A., Sadigh G., Kassaian S. E., Khatami S. M. R., Fotouhi A., Razavi S. A. H., Mansournia M. A., Yamini-Sharif A., Amirzadegan A., Salarifar M., Sadeghian S., Davoodi G., Borumand M. A., Esfehani F. A., Darabian S. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial. American Journal of Kidney Diseases. 2009;54(4):610–618. doi: 10.1053/j.ajkd.2009.05.016.
    1. Oliveira D. B. G. Prophylaxis against contrast-induced nephropathy. The Lancet. 1999;353(9165):1638–1639. doi: 10.1016/S0140-6736(98)90076-9.
    1. McCullough P. A., Wolyn R., Rocher L. L., Levin R. N., O'Neill W. W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. The American Journal of Medicine. 1997;103(5):368–375. doi: 10.1016/S0002-9343(97)00150-2.
    1. Taliercio C. P., Vlietstra R. E., Fisher L. D., Burnett J. C. Risks for renal dysfunction with cardiac angiography. Annals of Internal Medicine. 1986;104(4):501–504. doi: 10.7326/0003-4819-104-4-501.
    1. McCullough P. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheterization and Cardiovascular Interventions. 2006;67(3):335–343. doi: 10.1002/ccd.20658.
    1. Kato K., Sato N., Yamamoto T., Iwasaki Y.-K., Tanaka K., Mizuno K. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circulation Journal. 2008;72(9):1499–1505. doi: 10.1253/circj.CJ-07-1006.
    1. Nunag M., Brogan M., Garrick R. Mitigating contrast-induced acute kidney injury associated with cardiac catheterization. Cardiology in Review. 2009;17(6):263–269. doi: 10.1097/CRD.0b013e3181bc359d.
    1. Keaney J. J., Hannon C. M., Murray P. T. Contrast-induced acute kidney injury: how much contrast is safe? Nephrology Dialysis Transplantation. 2013;28(6):1376–1383. doi: 10.1093/ndt/gfs602.
    1. Cigarroa R. G., Lange R. A., Williams R. H., Hillis D. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. The American Journal of Medicine. 1989;86(C):649–652. doi: 10.1016/0002-9343(89)90437-3.
    1. Laskey W. K., Jenkins C., Selzer F., et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. Journal of the American College of Cardiology. 2007;50(7):584–590. doi: 10.1016/j.jacc.2007.03.058.
    1. Gurm H. S., Dixon S. R., Smith D. E., Share D., Lalonde T., Greenbaum A., Moscucci M. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. Journal of the American College of Cardiology. 2011;58(9):907–914. doi: 10.1016/j.jacc.2011.05.023.
    1. Safirstein R., Andrade L., Vieira J. M. Acetylcysteine and nephrotoxic effects of radiographic contrast agents—a new use for an old drug. The New England Journal of Medicine. 2000;343(3):210–212. doi: 10.1056/NEJM200007203430311.
    1. Lee H.-C., Sheu S.-H., Liu I.-H., Lee C.-C., Hsieh C.-C., Yen H.-W., Lai W.-T., Chang J.-G. Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. Journal of Nephrology. 2012;25(1):56–62. doi: 10.5301/JN.2011.7741.
    1. From A. M., Bartholmai B. J., Williams A. W., Cha S. S., Pflueger A., McDonald F. S. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic. Clinical Journal of the American Society of Nephrology. 2008;3(1):10–18. doi: 10.2215/CJN.03100707.
    1. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. The New England Journal of Medicine. 2000;343(3):180–184. doi: 10.1056/NEJM200007203430304.
    1. Baker C. S. R., Wragg A., Kumar S., de Palma R., Baker L. R. I., Knight C. J. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. Journal of the American College of Cardiology. 2003;41(12):2114–2118. doi: 10.1016/S0735-1097(03)00487-X.
    1. Durham J. D., Caputo C., Dokko J., Zaharakis T., Pahlavan M., Keltz J., Dutka P., Marzo K., Maesaka J. K., Fishbane S. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney International. 2002;62(6):2202–2207. doi: 10.1046/j.1523-1755.2002.00673.x.
    1. Allaqaband S., Tumuluri R., Malik A. M., Gupta A., Volkert P., Shalev Y., Bajwa T. K. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheterization and Cardiovascular Interventions. 2002;57(3):279–283. doi: 10.1002/ccd.10323.
    1. Goldenberg I., Shechter M., Matetzky S., Jonas M., Adam M., Pres H., Elian D., Agranat O., Schwammenthal E., Guetta V. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. European Heart Journal. 2004;25(3):212–218. doi: 10.1016/j.ehj.2003.11.011.
    1. Pannu N., Manns B., Lee H., Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney International. 2004;65(4):1366–1374. doi: 10.1111/j.1523-1755.2004.00516.x.
    1. Coyle L. C., Rodriguez A., Jeschke R. E., Simon-Lee A., Abbott K. C., Taylor A. J. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. The American Heart Journal. 2006;151(5):1032.e9–1032.e12. doi: 10.1016/j.ahj.2006.02.002.
    1. Ferrario F., Barone M. T., Landoni G., Genderini A., Heidemperger M., Trezzi M., Piccaluga E., Danna P., Scorza D. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy—a randomized controlled study. Nephrology Dialysis Transplantation. 2009;24(10):3103–3107. doi: 10.1093/ndt/gfp306.
    1. Gurm H. S., Smith D. E., Berwanger O., Share D., Schreiber T., Moscucci M., Nallamothu B. K. Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention. JACC: Cardiovascular Interventions. 2012;5(1):98–104. doi: 10.1016/j.jcin.2011.09.019.
    1. Spargias K., Alexopoulos E., Kyrzopoulos S., Iacovis P., Greenwood D. C., Manginas A., Voudris V., Pavlides G., Buller C. E., Kremastinos D., Cokkinos D. V. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110(18):2837–2842. doi: 10.1161/01.CIR.0000146396.19081.73.
    1. Alexopoulos E., Spargias K., Kyrzopoulos S., Manginas A., Pavlides G., Voudris V., Lerakis S., McLean D. S., Cokkinos D. V. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media. The American Journal of the Medical Sciences. 2010;339(1):25–30. doi: 10.1097/MAJ.0b013e3181c06e70.
    1. Sadat U., Usman A., Gillard J. H., Boyle J. R. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. Journal of the American College of Cardiology. 2013;62(23):2167–2175. doi: 10.1016/j.jacc.2013.07.065.
    1. Boscheri A., Weinbrenner C., Botzek B., Reynen K., Kuhlisch E., Strasser R. H. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clinical Nephrology. 2007;68(5):279–286. doi: 10.5414/CNP68279.
    1. Briguori C., Airoldi F., D'Andrea D., Bonizzoni E., Morici N., Focaccio A., Michev I., Montorfano M., Carlino M., Cosgrave J., Ricciardelli B., Colombo A. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115(10):1211–1217. doi: 10.1161/CIRCULATIONAHA.106.687152.
    1. Poletti P.-A., Saudan P., Platon A., Mermillod B., Sautter A.-M., Vermeulen B., Sarasin F. P., Becker C. D., Martin P.-Y. IV N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. American Journal of Roentgenology. 2007;189(3):687–692. doi: 10.2214/AJR.07.2356.
    1. Tasanarong A., Vohakiat A., Hutayanon P., Piyayotai D. New strategy of α-and γ-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrology Dialysis Transplantation. 2013;28(2):337–344. doi: 10.1093/ndt/gfs525.
    1. Veverka A., Nuzum D. S., Jolly J. L. Nebivolol: a third-generation β-adrenergic blocker. Annals of Pharmacotherapy. 2006;40(7-8):1353–1360. doi: 10.1345/aph.1G708.
    1. Sule S. S., Frishman W. Nebivolol: new therapy update. Cardiology in Review. 2006;14(5):259–264. doi: 10.1097/01.crd.0000223651.03023.8e.
    1. Toprak O., Cirit M., Tanrisev M., Yazici C., Canoz O., Sipahioglu M., Uzum A., Ersoy R., Sozmen E. Y. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrology Dialysis Transplantation. 2008;23(3):853–859. doi: 10.1093/ndt/gfm691.
    1. Avci E., Yeşil M., Bayata S., Postaci N., Arikan E., Cirit M. The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction. Anadolu Kardiyoloji Dergisi. 2011;11(7):613–617. doi: 10.5152/akd.2011.164.
    1. Günebakmaz Ö., Kaya M. G., Koc F., Akpek M., Kasapkara A., Inanc M. T., Yarlioglues M., Calapkorur B., Karadag Z., Oguzhan A. Does nebivolol prevent contrast-induced nephropathy in humans? Clinical Cardiology. 2012;35(4):250–254. doi: 10.1002/clc.21013.
    1. Khanal S., Attallah N., Smith D. E., Kline-Rogers E., Share D., O'Donnell M. J., Moscucci M. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. The American Journal of Medicine. 2005;118(8):843–849. doi: 10.1016/j.amjmed.2005.03.031.
    1. Patti G., Nusca A., Chello M., et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. The American Journal of Cardiology. 2008;101(3):279–285. doi: 10.1016/j.amjcard.2007.08.030.
    1. Leoncini M., Toso A., Maioli M., Tropeano F., Bellandi F. Statin treatment before percutaneous cononary intervention. Journal of Thoracic Disease. 2013;5(3):335–342. doi: 10.3978/j.issn.2072-1439.2013.05.09.
    1. Zhang B.-C., Li W.-M., Xu Y.-W. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Canadian Journal of Cardiology. 2011;27(6):851–858. doi: 10.1016/j.cjca.2011.05.005.
    1. Andreucci M. Statins in CIN: a problem at least partly solved? Giornale Italiano di Nefrologia. 2013;30(3)
    1. Sabbatini M., Pisani A., Uccello F., Serio V., Serù R., Paternò R., Cianciaruso B., Fuiano G., Andreucci M. Atorvastatin improves the course of ischemic acute renal failure in aging rats. Journal of the American Society of Nephrology. 2004;15(4):901–909. doi: 10.1097/.
    1. Al-Otaibi K. E., Al Elaiwi A. M., Tariq M., Al-Asmari A. K. Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxidative Medicine and Cellular Longevity. 2012;2012 doi: 10.1155/2012/831748.831748
    1. Quintavalle C., Fiore D., de Micco F., Visconti G., Focaccio A., Golia B., Ricciardelli B., Donnarumma E., Bianco A., Zabatta M. A., Troncone G., Colombo A., Briguori C., Condorelli G. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126(25):3008–3016. doi: 10.1161/CIRCULATIONAHA.112.103317.
    1. Han Y., Zhu G., Han L., Hou F., Huang W., Liu H., Gan J., Jiang T., Li X., Wang W., Ding S., Jia S., Shen W., Wang D., Sun L., Qiu J., Wang X., Li Y., Deng J., Li J., Xu K., Xu B., Mehran R., Huo Y. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. Journal of the American College of Cardiology. 2014;63(1):62–70. doi: 10.1016/j.jacc.2013.09.017.
    1. Leoncini M., Toso A., Maioli M., Tropeano F., Villani S., Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome) Journal of the American College of Cardiology. 2014;63(1):71–79. doi: 10.1016/j.jacc.2013.04.105.
    1. Acikel S., Muderrisoglu H., Yildirir A., Aydinalp A., Sade E., Bayraktar N., Bal U., Ozin B. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagulation and Fibrinolysis. 2010;21(8):750–757. doi: 10.1097/MBC.0b013e32834014a4.
    1. Patti G., Ricottini E., Nusca A., Colonna G., Pasceri V., D'Ambrosio A., Montinaro A., Di Sciascio G. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. The American Journal of Cardiology. 2011;108(1):1–7. doi: 10.1016/j.amjcard.2011.03.001.
    1. Marenzi G., Ferrari C., Marana I., Assanelli E., de Metrio M., Teruzzi G., Veglia F., Fabbiocchi F., Montorsi P., Bartorelli A. L. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC: Cardiovascular Interventions. 2012;5(1):90–97. doi: 10.1016/j.jcin.2011.08.017.
    1. Neumayer H. H., Junge W., Kufner A., Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrology Dialysis Transplantation. 1989;4(12):1030–1036.
    1. Russo D., Testa A., Della Volpe L., Sansone G. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron. 1990;55(3):254–257. doi: 10.1159/000185971.
    1. Solomon R., Werner C., Mann D., D'Elia J., Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. The New England Journal of Medicine. 1994;331(21):1416–1420. doi: 10.1056/NEJM199411243312104.
    1. Khoury Z., Schlicht J. R., Como J., Karschner J. K., Shapiro A. P., Mook W. J., Weber R. J. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy. 1995;15(1):59–65.
    1. Spangberg-Viklund B., Berglund J., Nikonoff T., Nyberg P., Skau T., Larsson R. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scandinavian Journal of Urology and Nephrology. 1996;30(1):63–68. doi: 10.3109/00365599609182351.
    1. Erley C. M., Duda S. H., Schlepckow S., Koehler J., Huppert P. E., Strohmaier W. L., Bohle A., Risler T., Osswald H. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney International. 1994;45(5):1425–1431. doi: 10.1038/ki.1994.186.
    1. Katholi R. E., Taylor G. J., McCann W. P., Woods W. T., Jr., Womack K. A., McCoy C. D., Katholi C. R., Moses H. W., Mishkel G. J., Lucore C. L., Holloway R. M., Miller B. D., Woodruff R. C., Dove J. T., Mikell F. L., Schneider J. A. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology. 1995;195(1):17–22. doi: 10.1148/radiology.195.1.7892462.
    1. Erley C. M., Duda S. H., Rehfuss D., Scholtes B., Bock J., Müller C., Osswald H., Risler T. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrology Dialysis Transplantation. 1999;14(5):1146–1149. doi: 10.1093/ndt/14.5.1146.
    1. Huber W., Ilgmann K., Page M., Hennig M., Schweigart U., Jeschke B., Lutilsky L., Weiss W., Salmhofer H., Classen M. Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology. 2002;223(3):772–779. doi: 10.1148/radiol.2233010609.
    1. Abizaid A. S., Clark C. E., Mintz G. S., et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. The American Journal of Cardiology. 1999;83(2):260–263. doi: 10.1016/S0002-9149(98)00833-9.
    1. Shammas N. W., Kapalis M. J., Harris M., McKinney D., Coyne E. P. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. Journal of Invasive Cardiology. 2001;13(11):738–740.
    1. Detrenis S., Meschi M., Musini S., Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: State of the art. Nephrology Dialysis Transplantation. 2005;20(8):1542–1550. doi: 10.1093/ndt/gfh868.
    1. Russo D., Minutolo R., Cianciaruso B., Memoli B., Conte G., de Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. Journal of the American Society of Nephrology. 1995;6(5):1451–1458.
    1. Wang A., Holcslaw T., Bashore T. M., Freed M. I., Miller D., Rudnick M. R., Szerlip H., Thames M. D., Davidson C. J., Shusterman N., Schwab S. J. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney International. 2000;57(4):1675–1680. doi: 10.1046/j.1523-1755.2000.00012.x.
    1. Clauser P., Harpey C. Antioxidant properties of an antiischaemic agent: trimetazidine. Advances in Experimental Medicine and Biology. 1990;264:247–250. doi: 10.1007/978-1-4684-5730-8_39.
    1. Elimadi A., Settaf A., Morin D., Sapena R., Lamchouri F., Cherrah Y., Tillement J.-P. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. The Journal of Pharmacology and Experimental Therapeutics. 1998;286(1):23–28.
    1. Aubert A., Bernard C., Clauser P., Harpey C., Vaudry H. Effect of phenazine methosulfate on electrophysiological activity of the semicircular canal: antioxidant properties of trimetazidine. European Journal of Pharmacology. 1989;174(2-3):215–225. doi: 10.1016/0014-2999(89)90314-2.
    1. Onbasili A. O., Yeniceriglu Y., Agaoglu P., Karul A., Tekten T., Akar H., Discigil G. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart. 2007;93(6):698–702. doi: 10.1136/hrt.2006.097477.
    1. Hans S. S., Hans B. A., Dhillon R., Dmuchowski C., Glover J. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. American Surgeon. 1998;64(5):432–436.
    1. Chamsuddin A. A., Kowalik K. J., Bjarnason H., Dietz C. A., Rosenberg M. S., Gomes M. D., McDermott C. M., Hunter D. W. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy. American Journal of Roentgenology. 2002;179(3):591–596. doi: 10.2214/ajr.179.3.1790591.
    1. Kini A. S., Mitre C. A., Kamran M., Suleman J., Kim M., Duffy M. E., Marmur J. D., Sharma S. K. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. The American Journal of Cardiology. 2002;89(8):999–1002. doi: 10.1016/S0002-9149(02)02259-2.
    1. Weisberg L. S., Kurnik P. B., Kurnik B. R. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney International. 1994;45:259–265. doi: 10.1038/ki.1994.32.
    1. Gare M., Haviv Y. S., Ben-Yehuda A., Rubinger D., Bdolah-Abram T., Fuchs S., Gat O., Popovtzer M. M., Gotsman M. S., Mosseri M. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. Journal of the American College of Cardiology. 1999;34(6):1682–1688. doi: 10.1016/S0735-1097(99)00422-2.
    1. Stone G. W., McCullough P. A., Tumlin J. A., et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. The Journal of the American Medical Association. 2003;290(17):2284–2291. doi: 10.1001/jama.290.17.2284.
    1. Kolyada A. Y., Liangos O., Madias N. E., Jaber B. L. Protective effect of erythropoietin against radiocontrast-induced renal tubular epithelial cell injury. The American Journal of Nephrology. 2008;28(2):203–209. doi: 10.1159/000110089.
    1. Goldfarb M., Rosenberger C., Shina A., Rosen S., Heyman S. A role for erythropoietin in the attenuation of radiocontrast-induced acute renal failure in rats. Renal Failure. 2006;28(4):345–350. doi: 10.1080/08860220600591420.
    1. Yokomaku Y., Sugimoto T., Kume S., Araki S.-I., Isshiki K., Chin-Kanasaki M., Sakaguchi M., Nitta N., Haneda M., Koya D., Uzu T., Kashiwagi A. Asialoerythropoietin prevents contrast-induced nephropathy. Journal of the American Society of Nephrology. 2008;19(2):321–328. doi: 10.1681/ASN.2007040481.
    1. Schindler R., Stahl C., Venz S., Ludat K., Krause W., Frei U. Removal of contrast media by different extracorporeal treatments. Nephrology Dialysis Transplantation. 2001;16(7):1471–1474. doi: 10.1093/ndt/16.7.1471.
    1. Lehnert T., Keller E., Gondolf K., Schäffner T., Pavenstädt H., Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrology Dialysis Transplantation. 1998;13(2):358–362. doi: 10.1093/oxfordjournals.ndt.a027830.
    1. Vogt B., Ferrari P., Schönholzer C., Marti H.-P., Mohaupt M., Wiederkehr M., Cereghetti C., Serra A., Huynh-Do U., Uehlinger D., Frey F. J. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. The American Journal of Medicine. 2001;111(9):692–698. doi: 10.1016/S0002-9343(01)00983-4.
    1. Esnault V. L. Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists. Nephrology Dialysis Transplantation. 2002;17(8):1362–1364. doi: 10.1093/ndt/17.8.1362.
    1. Andreucci M., Faga T., Pisani A., Sabbatini M., Michael A. The choice of the iodinated radiographic contrast media to prevent contrast-induced nephropathy. Advances in Nephrology. 2014;2014 doi: 10.1155/2014/691623.691623

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться